Drugs / LPCN 1148
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04874350 | Nov 2021 → Dec 2023 | cirrhosis of liver, muscular atrophy | Lipocine Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2025-05-22 | Lipocine Inc. | Results Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology lipocine.com ↗
Detailed results from the Phase 2 trial are published in the same issue of Hepatology (Vol. 81, Issue 6). |
| 2024-12-17 | Lipocine Inc. | Regulatory FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis lipocine.com ↗ |
| 2024-11-18 | Lipocine Inc. | Results Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session lipocine.com ↗
The results at 24 weeks showed that LPCN 1148 therapy resulted in a significant improvement in sarcopenia when compared with placebo. |
| 2024-06-10 | Lipocine Inc. | Results Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024 lipocine.com ↗
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that Phase 2 results on LPCN 1148 in cirrhosis were featured in a late breaking oral presentation at the European Association for the Study of Liver (EASL) Congress on Saturday, June 8 , in Milan, Italy . |
| 2024-03-28 | Lipocine Inc. | Results Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis lipocine.com ↗
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company today announced positive topline results from a Phase 2 clinical study of LPCN 1148. |
| 2023-11-13 | Lipocine Inc. | Results Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023 lipocine.com ↗
The data show that LPCN 1148 improved multiple additional clinically meaningful and surrogate outcomes, including hepatic encephalopathy. |
| 2023-07-27 | Lipocine Inc. | Results LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis lipocine.com ↗
Met primary endpoint: treatment with LPCN 1148 increased L3 skeletal muscle index (L3-SMI) relative to placebo (P <0.01) |
| 2020-05-05 | Lipocine Inc. | Regulatory FDA Clears LPCN 1148 IND Application for Phase 2 Cirrhosis Trial lipocine.com ↗ |
All press releases naming this drug 13 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LPCN 1148 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04874350 ↗ |
| Route | Oral | “Oral LPCN 1148 capsules, administered as BID.” NCT04874350 ↗ |